MX2019001930A - Ensayo para determinar el potencial para la autoasociacion de una proteina usando espectroscopia de nanoparticulas de autointeraccion dependiente de la concentracion. - Google Patents
Ensayo para determinar el potencial para la autoasociacion de una proteina usando espectroscopia de nanoparticulas de autointeraccion dependiente de la concentracion.Info
- Publication number
- MX2019001930A MX2019001930A MX2019001930A MX2019001930A MX2019001930A MX 2019001930 A MX2019001930 A MX 2019001930A MX 2019001930 A MX2019001930 A MX 2019001930A MX 2019001930 A MX2019001930 A MX 2019001930A MX 2019001930 A MX2019001930 A MX 2019001930A
- Authority
- MX
- Mexico
- Prior art keywords
- self
- protein
- concentration
- assay
- association
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 5
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 238000003556 assay Methods 0.000 title abstract 3
- 230000001419 dependent effect Effects 0.000 title abstract 2
- 239000002105 nanoparticle Substances 0.000 title abstract 2
- 238000004611 spectroscopical analysis Methods 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000003993 interaction Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
- G01N33/587—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N2021/258—Surface plasmon spectroscopy, e.g. micro- or nanoparticles in suspension
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plasma & Fusion (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
Abstract
Se proporcionan métodos para producir formulaciones de proteína de alta concentración que tienen estabilidad elevada. Ensayos para seleccionar proteínas y condiciones de formulación que tienen atributos autorepulsivos elevados se usan como una etapa temprana en el proceso de elaboración. Específicamente, un método de espectroscopía de nanopartículas de autointeracción dependiente de la concentración de proteínas se emplea como un ensayo de interacción coloidal de proteínas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662376788P | 2016-08-18 | 2016-08-18 | |
| PCT/US2017/047630 WO2018035470A1 (en) | 2016-08-18 | 2017-08-18 | Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019001930A true MX2019001930A (es) | 2019-07-04 |
Family
ID=59746357
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019001930A MX2019001930A (es) | 2016-08-18 | 2017-08-18 | Ensayo para determinar el potencial para la autoasociacion de una proteina usando espectroscopia de nanoparticulas de autointeraccion dependiente de la concentracion. |
| MX2023013583A MX2023013583A (es) | 2016-08-18 | 2019-02-15 | Ensayo para determinar el potencial para la autoasociacion de una proteina usando espectroscopia de nanoparticulas de autointeraccion dependiente de la concentracion. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013583A MX2023013583A (es) | 2016-08-18 | 2019-02-15 | Ensayo para determinar el potencial para la autoasociacion de una proteina usando espectroscopia de nanoparticulas de autointeraccion dependiente de la concentracion. |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11428695B2 (es) |
| EP (2) | EP3500856B1 (es) |
| JP (3) | JP6959327B2 (es) |
| KR (3) | KR102717462B1 (es) |
| CN (2) | CN115468919A (es) |
| AU (2) | AU2017313150B2 (es) |
| BR (1) | BR112019003175A2 (es) |
| CA (1) | CA3032361A1 (es) |
| DK (2) | DK3500856T3 (es) |
| EA (1) | EA201990316A1 (es) |
| ES (2) | ES2974961T3 (es) |
| FI (1) | FI3761035T3 (es) |
| HU (2) | HUE052805T2 (es) |
| IL (2) | IL307435A (es) |
| MX (2) | MX2019001930A (es) |
| PL (2) | PL3761035T3 (es) |
| SG (1) | SG11201900895QA (es) |
| WO (1) | WO2018035470A1 (es) |
| ZA (1) | ZA201901035B (es) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11428695B2 (en) | 2016-08-18 | 2022-08-30 | Regeneron Pharmaceuticals, Inc. | Concentration-dependent self-interaction assay |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200275A1 (ar) | 2018-05-10 | 2020-11-02 | Regeneron Pharma | صيغ تحتوي على بروتين اندماج لمستقبلvegf مرتفعة التركيز |
| CN113588582B (zh) * | 2020-04-30 | 2024-05-14 | 上海药明生物技术有限公司 | 蛋白质样品浓度测定方式选择法及测定方法 |
| WO2023095154A1 (en) * | 2021-11-24 | 2023-06-01 | Sensoville Biotech Pvt Ltd | Method for determining changes in a protein's structure |
| WO2023141319A1 (en) * | 2022-01-24 | 2023-07-27 | Amgen Inc. | Methods for detecting antibody self-association |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US771997A (en) | 1903-11-21 | 1904-10-11 | Alfred Palm | Lathe attachment. |
| US4254102A (en) * | 1975-09-08 | 1981-03-03 | Plough, Inc. | Substantive PABA compositions |
| US4080264A (en) | 1976-03-01 | 1978-03-21 | Massachusetts Institute Of Technology | Immunoassay by light scattering spectroscopy |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US7514938B2 (en) | 2004-05-11 | 2009-04-07 | Board Of Regents Of The University And College System Of Nevada, On Behalf Of The University Of Nevada, Reno | Dielectric relaxation spectroscopy apparatus and methods of use |
| TW200621282A (en) | 2004-08-13 | 2006-07-01 | Wyeth Corp | Stabilizing formulations |
| WO2007121363A2 (en) | 2006-04-13 | 2007-10-25 | Mississippi State University | An optical apparatus for simultaneously measuring the scattering and concentration signals of macromolecules in a flow cell |
| CN101522219A (zh) | 2006-10-12 | 2009-09-02 | 惠氏公司 | 改变抗体溶液中离子强度以减少乳光/聚集物 |
| ES2522615T3 (es) | 2007-06-04 | 2014-11-17 | Regeneron Pharmaceuticals, Inc. | Regiones de expresión y estabilidad potenciadas |
| CA2700378A1 (en) * | 2007-09-21 | 2009-03-29 | Cytimmune Sciences, Inc. | Nanotherapeutic colloidal metal compositions and methods |
| US20110305765A1 (en) * | 2008-11-21 | 2011-12-15 | Board Of Regents, The University Of Texas System | Preparation and methodology of silk fibroin nanoparticles |
| WO2014192937A1 (ja) * | 2013-05-30 | 2014-12-04 | 公立大学法人大阪府立大学 | 被検出物質の検出装置および方法 |
| CN111202711B (zh) * | 2013-09-11 | 2022-06-21 | 伊戈尔生物药品股份有限公司 | 包含有机磷酸酯的液体蛋白质制剂 |
| WO2015196091A1 (en) | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| CN104062287B (zh) | 2014-07-01 | 2017-08-08 | 福建工程学院 | 一种基于纳米金催化的化学发光分析检测铁蛋白的方法 |
| MA40861A (fr) * | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| WO2016115475A1 (en) * | 2015-01-18 | 2016-07-21 | Biogen Ma Inc. | Anti-cd40 antibody formulations |
| PL3761035T3 (pl) | 2016-08-18 | 2024-06-24 | Regeneron Pharmaceuticals, Inc. | Test do określania potencjału samoasocjacji białka za pomocą spektroskopii zależnych od stężenia samoodziaływań nanocząstek |
-
2017
- 2017-08-18 PL PL20191942.0T patent/PL3761035T3/pl unknown
- 2017-08-18 KR KR1020237016537A patent/KR102717462B1/ko active IP Right Grant
- 2017-08-18 HU HUE17761159A patent/HUE052805T2/hu unknown
- 2017-08-18 MX MX2019001930A patent/MX2019001930A/es unknown
- 2017-08-18 CN CN202211108451.8A patent/CN115468919A/zh active Pending
- 2017-08-18 EP EP17761159.7A patent/EP3500856B1/en active Active
- 2017-08-18 BR BR112019003175A patent/BR112019003175A2/pt unknown
- 2017-08-18 ES ES20191942T patent/ES2974961T3/es active Active
- 2017-08-18 KR KR1020227030436A patent/KR102534506B1/ko active IP Right Grant
- 2017-08-18 IL IL307435A patent/IL307435A/en unknown
- 2017-08-18 EP EP20191942.0A patent/EP3761035B1/en active Active
- 2017-08-18 KR KR1020197006376A patent/KR102441221B1/ko active IP Right Grant
- 2017-08-18 IL IL264640A patent/IL264640B2/en unknown
- 2017-08-18 US US16/326,238 patent/US11428695B2/en active Active
- 2017-08-18 SG SG11201900895QA patent/SG11201900895QA/en unknown
- 2017-08-18 JP JP2019508809A patent/JP6959327B2/ja active Active
- 2017-08-18 ES ES17761159T patent/ES2837093T3/es active Active
- 2017-08-18 DK DK17761159.7T patent/DK3500856T3/da active
- 2017-08-18 HU HUE20191942A patent/HUE066064T2/hu unknown
- 2017-08-18 DK DK20191942.0T patent/DK3761035T3/da active
- 2017-08-18 WO PCT/US2017/047630 patent/WO2018035470A1/en unknown
- 2017-08-18 PL PL17761159T patent/PL3500856T3/pl unknown
- 2017-08-18 FI FIEP20191942.0T patent/FI3761035T3/fi active
- 2017-08-18 CN CN201780050825.6A patent/CN109661577B/zh active Active
- 2017-08-18 AU AU2017313150A patent/AU2017313150B2/en active Active
- 2017-08-18 EA EA201990316A patent/EA201990316A1/ru unknown
- 2017-08-18 CA CA3032361A patent/CA3032361A1/en active Pending
-
2019
- 2019-02-15 MX MX2023013583A patent/MX2023013583A/es unknown
- 2019-02-18 ZA ZA2019/01035A patent/ZA201901035B/en unknown
-
2021
- 2021-10-07 JP JP2021165510A patent/JP7321227B2/ja active Active
-
2022
- 2022-07-20 US US17/868,983 patent/US11988668B2/en active Active
-
2023
- 2023-07-25 JP JP2023120438A patent/JP2023139189A/ja active Pending
- 2023-12-04 AU AU2023274236A patent/AU2023274236A1/en active Pending
-
2024
- 2024-04-16 US US18/637,055 patent/US20240280582A1/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11428695B2 (en) | 2016-08-18 | 2022-08-30 | Regeneron Pharmaceuticals, Inc. | Concentration-dependent self-interaction assay |
| US11988668B2 (en) | 2016-08-18 | 2024-05-21 | Regeneron Pharmaceuticals, Inc. | Concentration-dependent self-interaction assay |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201901035B (en) | Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy | |
| CY1123642T1 (el) | Αντισωματα enanti-pd-1 | |
| GEP20237513B (en) | Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof | |
| GB2569252A (en) | Methods of combining the detection of biomolecules into a single assay using fluorescent in situ sequencing | |
| NZ744333A (en) | Anti-c5 antibodies and methods of use | |
| CY1125697T1 (el) | Σταθερες, υδατικες φαρμακοτεχνικες μορφες αντισωματων | |
| BR112018075516A2 (pt) | purificação de anticorpos multiespecíficos | |
| CL2016002105A1 (es) | Método in vitro para determinar un pronóstico pobre en un paciente que tiene melanoma que comprende: (a) detectar el nivel de expresión de un ligando similar a delta 3 (dll3) en una muestra, donde la detección comprende poner en contacto la muestra con un anticuerpo anti-dll3. | |
| BR112018005164A2 (pt) | anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, formulação farmacêutica, uso do anticorpo e método de tratamento de um indivíduo que tem câncer | |
| EA201791366A1 (ru) | Антитела к c5 и способы их применения | |
| CL2016002004A1 (es) | Anticuerpos anti-jagged1 y métodos de uso | |
| BR112016023769A2 (pt) | célula hospedeira recombinante para a expressão de proteínas de interesse | |
| EA201591131A1 (ru) | Днк-конструкции антитела и способ их применения | |
| BR112015032736A2 (pt) | inibidores de bromodomínio cristalino | |
| EA201790877A1 (ru) | Подобный йогурту высокобелковый продукт на основе белка молочной сыворотки, ингредиент, подходящий для его получения, а также способ получения | |
| BR112018006562A2 (pt) | anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, conjugado e uso de um anticorpo | |
| AR091098A1 (es) | ANTICUERPOS E INMUNOCONJUGADOS CONTRA Ly6E Y METODOS DE USO | |
| EA201791424A1 (ru) | Получение белка | |
| WO2018081592A3 (en) | Compositions and methods for the production of compounds | |
| BR112016014756A8 (pt) | formulação de selante compreendendo fibrinogênio e zimogênios, seu método de fabricação, recipiente e uso | |
| MA44593A1 (fr) | Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations | |
| CA2894869C (en) | Solution formulations of engineered anti-il-23p19 antibodies | |
| SG11201803898SA (en) | Anti-pcsk9 antibody and use thereof | |
| EA201891594A1 (ru) | Антитела к il-17c | |
| WO2019066617A3 (ko) | 항 c-met 항체 및 이의 용도 |